These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34741929)

  • 1. Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
    Samsky MD; Mentz RJ; Stebbins A; Lokhnygina Y; Aday AW; Pagidipati NJ; Jones WS; Katona BG; Patel MR; Holman RR; Hernandez AF; Gutierrez JA
    Atherosclerosis; 2021 Dec; 338():1-6. PubMed ID: 34741929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
    Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
    Mentz RJ; Bethel MA; Merrill P; Lokhnygina Y; Buse JB; Chan JC; Felício JS; Goodman SG; Choi J; Gustavson SM; Iqbal N; Lopes RD; Maggioni AP; Öhman P; Pagidipati NJ; Poulter NR; Ramachandran A; Reicher B; Holman RR; Hernandez AF;
    J Am Heart Assoc; 2018 Oct; 7(19):e009304. PubMed ID: 30371301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
    Bethel MA; Stevens SR; Buse JB; Choi J; Gustavson SM; Iqbal N; Lokhnygina Y; Mentz RJ; Patel RA; Öhman P; Schernthaner G; Lecube A; Hernandez AF; Holman RR
    Circulation; 2020 Apr; 141(17):1360-1370. PubMed ID: 32098501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
    Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
    Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
    Regan JA; Mentz RJ; Nguyen M; Green JB; Truby LK; Ilkayeva O; Newgard CB; Buse JB; Sourij H; Sjöström CD; Sattar N; McGarrah RW; Zheng Y; McGuire DK; Standl E; Armstrong P; Peterson ED; Hernandez AF; Holman RR; Shah SH
    JCI Insight; 2023 Sep; 8(17):. PubMed ID: 37552540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
    Clegg LE; Jing Y; Penland RC; Boulton DW; Hernandez AF; Holman RR; Vora J
    Diabetes Obes Metab; 2021 May; 23(5):1101-1110. PubMed ID: 33394543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
    Gutierrez JA; Scirica BM; Bonaca MP; Steg PG; Mosenzon O; Hirshberg B; Im K; Raz I; Braunwald E; Bhatt DL
    Am J Cardiol; 2019 Jan; 123(1):145-152. PubMed ID: 30366601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
    Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
    Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
    Giugliano D; Meier JJ; Esposito K
    Diabetes Obes Metab; 2019 May; 21(5):1081-1087. PubMed ID: 30609236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
    Cherney DZI; Repetto E; Wheeler DC; Arnold SV; MacLachlan S; Hunt PR; Chen H; Vora J; Kosiborod M
    Am J Nephrol; 2020; 51(1):74-82. PubMed ID: 31812955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study.
    Orozco-Beltrán D; Navarro-Pérez J; Cebrián-Cuenca AM; Álvarez-Guisasola F; Caride-Miana E; Mora G; Quesada JA; López-Pineda A; Cardona-Llorens AF; Redón J; Gil-Guillen VF; Fernández A; Carratalá-Munuera C
    Prim Care Diabetes; 2020 Dec; 14(6):678-684. PubMed ID: 32605878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Bonora BM; Avogaro A; Fadini GP
    Acta Diabetol; 2019 Sep; 56(9):1051-1060. PubMed ID: 30993527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.